Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inmed Pharmaceuticals Inc (NQ: INM )

0.2523 +0.0143 (+6.01%)
Streaming Delayed Price Updated: 3:58 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Inmed Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Working on Answer to Mass Production of Rare, Otherwise Depleted Cannabinoid Opportunities
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InMed Pharmaceuticals Inc. (NASDAQ: INM) Files International Patent Application for Treating Neurodegenerative Diseases Using a New Rare Cannabinoid
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Results, Business Updates for Q1 2022
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Files PCT Application for Treating Neurodegenerative Disease Using Rare Cannabinoid
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production
Via Investor Brand Network
Topics Initial Public Offering
Exposures Securities Market
Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production
Via CannabisNewsWire
Topics Initial Public Offering
Exposures Securities Market
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Completion of BayMedica Acquisition
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Completion of BayMedica Acquisition
Via CannabisNewsWire
CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Poised to Become Global Leader in Manufacture of Rare Cannabinoids
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Begins Phase 2 Clinical Trial Evaluating CBN in the EB Treatment
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Begins Phase 2 Clinical Trial Evaluating CBN in the EB Treatment
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Eyes Commercial Plans to Become B2B Wholesale Supplier of Rare Cannabinoids
Via Investor Brand Network
Topics Supply Chain
Exposures Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Eyes Commercial Plans to Become B2B Wholesale Supplier of Rare Cannabinoids
Via CannabisNewsWire
Topics Supply Chain
Exposures Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Release FY 2021 Financial Report and Corporate Update
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Release FY 2021 Financial Report and Corporate Update
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release FY 2021 Financial Report, Acquire BayMedia
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release FY 2021 Financial Report, Acquire BayMedia
Via Investor Brand Network
InMed Pharmaceuticals (INM): Acquiring BayMedica
LONDON, UK / ACCESSWIRE / September 20, 2021 / InMed has announced that it has entered into a definitive agreement to acquire BayMedica, a private US-based company that is focusing on the manufacture... 
From Edison Investment Research Limited
Via AccessWire
InMed Pharmaceuticals Inc. (NASDAQ: INM) Signs Definitive Agreement to Acquire 100% of BayMedica Inc., Positioning it to Stand Distinct in Rare Cannabinoids Manufacturing, Become a Revenue-Generating Company, Expand Drug Development Capabilities
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters Definitive Agreement for ‘Transformative’ Acquisition of Leading Manufacturer of Rare Cannabinoids
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Slated for Live Webcast at VirtualInvestorConferences.com
Via CannabisNewsWire
InMed Pharmaceuticals Inc. (NASDAQ: INM) Presents CBN-Based Treatment for Glaucoma at H.C. Wainwright Ophthalmology Virtual Conference
Via CannabisNewsWire
Topics Cannabis
Exposures Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright Ophthalmology Virtual Conference
Via CannabisNewsWire
InMed Pharmaceuticals Inc. (NASDAQ: INM) and Its Quest to Build an Industry-Leading, Rare Cannabinoid Enterprise
Via CannabisNewsWire
420 with CNW — Patients with High-Grade Gliomas Register Improved Quality of Life after Using Medical Marijuana
Via CannabisNewsWire
Topics Cannabis
Exposures Cannabis
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Continues Optimization of IntegraSyn(TM) to Increase Cannabinoid Yield
Via CannabisNewsWire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.